Mario de Jesús Noh Burgos

Dr. Mario de Jesús Noh Burgos

HOSPITAL REGIONAL DE ALTA ESPECIALIDAD (HRAEPY), Mérida, Yucatán, Mexico
+1
orcid
Ph.D. in Sciences.

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2025 in Molecules
Verified
Journal Article
Open access
PDF file
Mario de Jesús Noh BurgosMario de Jesús Noh Burgos
Mario de Jesús Noh Burgos
SGSergio García-Sánchez
Sergio García-Sánchez
FTFernando J Tun-Rosado
Fernando J Tun-Rosado
ACANTONIETA CHAVEZ-GONZALEZ
ANTONIETA CHAVEZ-GONZALEZ
SPSergio R. Peraza-Sánchez
Sergio R. Peraza-Sánchez
RMRosa Moo-Puc
Rosa Moo-Puc
Current treatments against leukemia present several limitations, prompting the search for new therapeutic agents, particularly those derived from natural products. In this context, structural modifications were performed on the triterpene 3α,24-dihydroxylup-20(29)-en-28-oic acid (T1), isolated from Phoradendron wattii. Among the five derivatives obtained, 3α,24-dihydroxy-30-oxolup-20(29)-en-28-oic acid (T1c) exhibited the highest activity, with an IC50 value of 12.90 ± 0.1 µM against THP-1 cells. T1c significantly reduced cell viability in both acute lymphoblastic leukemia (CCRF-CEM, REH, JURKAT, and MOLT-4) and acute myeloid leukemia (THP-1) cell lines, inducing apoptosis after 48 h of treatment, while showing minimal cytotoxicity toward normal mononuclear cells (MNCs). In silico molecular docking studies were conducted against three key protein targets: BCL-2 (B-cell lymphoma 2), EGFR (epidermal growth factor receptor, tyrosine kinase domain), and FLT3 (FMS-like tyrosine kinase 3). The lowest binding energies (kcal/mol) observed were as follows: T1–BCL-2: −10.12, EGFR: −12.75, FLT3: −14.05; T1c–BCL-2: −10.23, EGFR: −14.50, FLT3: −14.07; T2–BCL-2: −11.59, EGFR: −15.00, FLT3: −14.03. These findings highlight T1c as a promising candidate in the search for anti-leukemic drugs which deserves further study.

20 March 2025 in Natural Product Communications
Verified
Journal Article
Open access
Mario de Jesús Noh BurgosMario de Jesús Noh Burgos
Mario de Jesús Noh Burgos
SGSergio García-Sánchez
Sergio García-Sánchez
FTFernando J. Tun-Rosado
Fernando J. Tun-Rosado
ACANTONIETA CHAVEZ-GONZALEZ
ANTONIETA CHAVEZ-GONZALEZ
RMRosa Moo-Puc
Rosa Moo-Puc
CNCarlos Javier Quintal Novelo
Carlos Javier Quintal Novelo
Introduction: Leukemia is among the most common types of cancer. Currently, the main anti-leukemia treatments have significant drawbacks, which has led to the search for new and better drugs, especially those developed from natural products. Objective: The aim of this work was to perform simple modifications to a lupane-type pentacyclic triterpene isolated from Phoradendron wattii , in order to generate new semi-synthetic analogues for their possible effect against a panel of leukemia cell lines. Methods: Simple structural modifications on the triterpene 3 α ,23- O -isopropylidenyl-3 α ,23-dihydroxylup-20(29)-en-28-oic acid ( T2 ) isolated from Phoradendron wattii were performed and evaluated against a panel of leukemia cell lines and normal mononuclear cells (MNC). In addition, molecular docking analysis was used to better understand the possible mechanism of action, employing key molecular targets used in the search for compounds with anti-leukemic activity (BCL-2 and EGFR). Results: Of the all derivatives synthetized ( T2a - T2f ), the compound ( T2e ), 3 α ,23-dihydroxy-30-oxolup-20(29)-en-28-ol, showed inhibition in leukemia cell lines (CCRF-CEM, REH, JURKAT, MOLT-4, and THP-1) and induction of death by apoptosis to different degrees. Moreover, it showed a minor cytotoxic effect on MNC and was found to interact with BCL-2 and EGFR in silico . Conclusion: The present work shows that simple modifications at promising sites in the lupane-type pentacyclic triterpene can generate derivatives with enhanced biological activity against leukemia cell lines. The T2e derivative is a promising candidate for future research.

10 July 2026 in Journal of Imaging
Verified
Journal Article
Open access
PDF file
Mario de Jesús Noh BurgosMario de Jesús Noh Burgos
Mario de Jesús Noh Burgos
JCJuan B. Chalé-Dzul
Juan B. Chalé-Dzul
LOLeticia Olivera-Castillo
Leticia Olivera-Castillo
CPCesar Puerto-Castillo
Cesar Puerto-Castillo
Nina Mendez-DominguezNina Mendez-Dominguez
Nina Mendez-Dominguez
RMRosa Moo-Puc
Rosa Moo-Puc
Magnetic resonance cholangiopancreatography (MRCP) is widely used for biliopancreatic imaging; however, hyperintense gastrointestinal fluids in heavily T2-weighted sequences may interfere with visualization of the biliary and pancreatic ducts. Natural manganese-containing beverages have been investigated in MRCP-related imaging contexts, and yerba mate (Ilex paraguariensis A. St.-Hil.) has been studied to this end. However, its concentration- and sequence-dependent signal behavior under MRCP-like phantom conditions remains insufficiently characterized. This preclinical phantom study evaluated the concentration- and sequence-dependent MRI signal intensity behavior of an aqueous extract of Ilex paraguariensis. The extract was characterized by means of elemental analysis, total manganese and iron quantification, total phenolic content, antioxidant capacity, and LC-ESI-MS analysis. MRI phantom experiments were run at different extract concentrations using T1-weighted, T2-weighted, and single-shot turbo spin echo (SSHTSE) sequences. The dried extract contained 1.22 ± 0.04 mg/g total manganese and 0.40 ± 0.01 mg/g total iron. Calculated total Mn concentrations in phantom dilutions ranged from 0.06 to 0.97 mg/dL. The extract showed concentration- and sequence-dependent signal behavior, with T1-weighted signal enhancement and progressive signal suppression in T2-weighted and SSHTSE sequences. No T1/T2 mapping or r1/r2 relaxivity measurements were performed. LC-ESI-MS identified MS1-based putatively assigned phenolic features without MS/MS confirmation of extract peaks. Ilex paraguariensis aqueous extract showed preliminary concentration- and sequence-dependent MRI signal intensity changes under phantom conditions, including signal suppression in MRCP-like heavily T2-weighted sequences. These findings do not establish clinical applicability, safety, tolerability, comparative efficacy, or improved duct visualization. Further studies are needed, incorporating relaxometric measurements, comparator agents, formulation assessment, in vivo evaluation, and clinical validation.